Clinical Trial Update: Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update evaluating total neoadjuvant therapy combined with the PD-1 inhibitor adebrelimab for locally advanced resectable esophageal squamous ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Adebrelimab (adebrelimab)

Snippet

Sponsor: YIN LI | Conditions: Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING